CYRX vs IART vs HOLX vs LQDA

For growth investors, Hologic, Inc.

(HOLX) is the stronger pick with 1. 7% revenue growth year-over-year, versus -24. 5% for Cryoport, Inc. (CYRX). Cryoport, Inc. (CYRX) offers the better valuation at 9. 1x trailing P/E, making it the more compelling value choice. Analysts rate Cryoport, Inc. (CYRX) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Cryoport, Inc.

(CYRX) is the cheapest at 9. 1x versus Hologic, Inc. at 30. 5x. On forward P/E, Integra LifeSciences Holdings Corporation is actually cheaper at 5. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Liquidia Corporation (LQDA) delivered a total return of +1495%, compared to -81.

7% for Integra LifeSciences Holdings Corporation (IART). Over 10 years, the gap is even starker: CYRX returned +557. 7% versus IART's -63. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus Integra LifeSciences Holdings Corporation's 2. 34β — meaning IART is approximately 469% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Cryoport, Inc. (CYRX) carries a lower debt/equity ratio of 46% versus 195% for Integra LifeSciences Holdings Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hologic, Inc.

(HOLX) is pulling ahead at 1. 7% versus -24. 5% for Cryoport, Inc. (CYRX). On earnings-per-share growth, the picture is similar: Cryoport, Inc. grew EPS 163. 3% year-over-year, compared to -73. 6% for Integra LifeSciences Holdings Corporation. Over a 3-year CAGR, LQDA leads at 2. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cryoport, Inc.

(CYRX) is the more profitable company, earning 39. 9% net margin versus -931. 7% for Liquidia Corporation — meaning it keeps 39. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -866. 6% for LQDA. At the gross margin level — before operating expenses — HOLX leads at 61. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Integra LifeSciences Holdings Corporation (IART) trades at 5.

8x forward P/E versus 17. 5x for Liquidia Corporation — 11. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LQDA: 19. 8% to $50. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). Integra LifeSciences Holdings Corporation (IART) carries a higher beta of 2. 34 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, IART: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CYRX (Industrials) and IART (Healthcare) and HOLX (Healthcare) and LQDA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CYRX is a small-cap deep-value stock; IART is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock; LQDA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.